allogeneic mesenchymal stem cells
Cell therapyexperimental
MSC may refer to: — Wikipedia
Clinical trial activity
46 trials · 67 clinical orgs · 0 marketing orgs
Phase 1
29
Phase 2
28
Phase 3
4
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00827398)
Timeline
Indications
Studied for
- Abortion, Habitual · Phase 1/Phase 2
- Aggressive Periodontitis · Phase 1/Phase 2
- Alzheimer Disease · Phase 2
- Bone and Bones · Phase 1/Phase 2
- Bone Diseases · Early Phase 1
- Burns · Phase 1/Phase 2
- Cardiomyopathy, Dilated · Phase 1
- Cerebral Hemorrhage · Phase 1
- Chronic Limb-Threatening Ischemia · Phase 2
- Chronic Periodontitis · Phase 1/Phase 2
- Cornea · Phase 1
- Corneal Diseases · Phase 1
- Coronavirus Infections · Phase 1
- COVID-19 · Phase 2/Phase 3
- Crohn Disease · Phase 2/Phase 3
- Dementia · Phase 2
- Diabetes Mellitus · Phase 1/Phase 2
- Diabetes Mellitus, Type 1 · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 1/Phase 2
- Diabetic Foot · Phase 2
- Epidermolysis Bullosa Dystrophica · Phase 1/Phase 2
- Fistula · Phase 2/Phase 3
- Fractures, Bone · Phase 1/Phase 2
- Graft vs Host Disease · Phase 2
- Heart Diseases · Phase 2
- Hemorrhagic Stroke · Phase 1
- Hidradenitis Suppurativa · Phase 1/Phase 2
- Intervertebral Disc Degeneration · Phase 2
- Ischemic Stroke · Phase 1/Phase 2
- Leg Length Inequality · Phase 1
- Low Back Pain · Phase 2
- Mesenchymal Stem Cells · Phase 2
- Myocardial Ischemia · Phase 1/Phase 2
- Osteoarthritis, Knee · Phase 3
- Osteonecrosis · Phase 1
- Pneumonia, Viral · Phase 1
- Pseudarthrosis · Phase 1/Phase 2
- Pulmonary Emphysema · Phase 2
- Renal Insufficiency, Chronic · Phase 1/Phase 2
- Rhinitis, Allergic · Phase 1
- Safety · Phase 1
- Stroke · Phase 1/Phase 2
- Tuberculosis, Spinal · Phase 2
- Urinary Incontinence, Stress · Phase 1
- Xerostomia · Phase 1
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMSC ↗
Also known as
- msc
- msc
- plasma reach protein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07240987 | Phase 1/Phase 2 (Phase 2) | Nov 15, 2025 | People's Liberation Army of China |
| NCT06886646 | Phase 2 | Sep 15, 2025 | Assistance Publique - Hôpitaux de Paris |
| NCT06911281 | Phase 1 | Jun 30, 2025 | Huazhong University of Science and Technology |
| NCT06781333 | Phase 2 | Mar 1, 2025 | University of Miami |
| NCT06738576 | Phase 1 | Dec 11, 2024 | Universidad Autonoma de Madrid |
| NCT06464588 | Phase 1 | Oct 31, 2024 | Emory University, The Marcus Foundation |
| NCT06231771 | Phase 1/Phase 2 (Phase 2) | May 31, 2024 | Supergenics Life Science Sdn. Bhd. |
| NCT06012604 | Phase 1 | Sep 30, 2023 | Blood Transfusion Centre of Slovenia, University of Ljubljana |
| NCT05728346 | N/A | Sep 1, 2023 | Guangzhou Medical University |
| NCT05333029 | Phase 2 | Apr 30, 2023 | Case Western Reserve University |
| NCT05520125 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2022 | Belarusian Medical Academy of Post-Graduate Education, Government of Belarus, National Academy of Sciences of Belarus |
| NCT05520112 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2022 | Belarusian Medical Academy of Post-Graduate Education, Government of Belarus, National Academy of Sciences of Belarus |
| NCT05934825 | Phase 1/Phase 2 (Phase 2) | Oct 26, 2022 | Andalusian Network for Design and Translation of Advanced Therapies |
| NCT05286255 | Phase 1 | May 4, 2022 | Medical University of South Carolina |
| NCT05233774 | Phase 2 | Dec 28, 2021 | bioRASI, LLC, Longeveron LLC |
| NCT04776239 | Phase 1/Phase 2 (Phase 2) | Aug 16, 2021 | National Heart, Lung, and Blood Institute (NHLBI), University of Miami |
| NCT06103409 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2021 | Hospital Central Dr. Plácido D. Rodriguez Rivero, San Felipe, Yaracuy, Instituto Venezolano de Investigaciones Cientificas |
| NCT05086939 | Phase 3 | May 26, 2021 | Institut d'Investigacions Biomèdiques August Pi i Sunyer, Instituto de Estudios de Ciencias de la Salud de Castilla y León (IECSCYL), Spanish Clinical Research Network, University of Barcelona, University of Salamanca |
| NCT04780685 | Phase 2 | Mar 20, 2021 | bioRASI, LLC, Providence Saint John's Health Center, Stemedica |
| NCT04626583 | Phase 1 | Jan 15, 2021 | Department of Defense, University of Illinois at Chicago |
Showing 20 of 46 trials
Page 1 / 3
Organizations
Research & Development (67)
67 organizations
Page 1 / 4